Lance Alstodt - May 2, 2022 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
President, CEO, COB, Director
Signature
/s/ Lance Alstodt
Stock symbol
BRTX
Transactions as of
May 2, 2022
Transactions value $
$1,579
Form type
4
Date filed
5/2/2022, 05:14 PM
Previous filing
Mar 22, 2022
Next filing
May 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRTX Common Stock Purchase $787 +200 +0.11% $3.94 176K May 2, 2022 Direct F1
transaction BRTX Common Stock Purchase $792 +200 +0.11% $3.96 176K May 2, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BRTX Stock Option 293K May 2, 2022 Common Stock 293K $13.50 Direct F2
holding BRTX Stock Option 42.1K May 2, 2022 Common Stock 42.1K $13.50 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 109,227 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares beginning on May 18, 2022 and continuing monthly through September 18, 2022, 1,036 shares beginning on October 18, 2022 and continuing monthly through February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
F2 The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F3 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.